ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / SCLX / earnings
DYAI (31) ABOS (33) PLUR (34) JSPR (36) ⌘ Pro Terminal →

Scilex Holding Company (SCLX) Next Earnings Date & Expected ±12.5% Move

$1.85 -10.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.81

Scilex Holding Company (SCLX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $15.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SCLX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SCLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Scilex Holding Company (NASDAQ: SCLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.85 (-10.19% 1D, market cap $15.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCLX ranks #471 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SCLX compare to DYAI and ABOS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and ABOS (Acumen Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SCLX?
▼

Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.81 (-2.02%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 12.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (12)Whales (3)SEC (8)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$18 Bull$2 Base$1 Bear
📬 FREE SCLX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCLX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY SCLX SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+12/20 pts (30% of score)

SEC XBRL FY 2025 (10-K): 12.2% FCF Margin ($3.7M FCF) & 415.8% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+9/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 45% Net Buy • Disciplined Float (-0.40% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$2.88-12.2% Next Q
Q2 (-2Q)
45
Grade D$2.53-19% Next Q
Q3 (-1Q)
43
Grade D$2.05-9.8% Next Q
Current
40
Grade D-$1.85-7.4% Hist 90D α
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SCLX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SCLX currently carries a cautious 40/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.02) and Max Pain ($1.94) forces dealer call-delta covering toward $17.65.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCLX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SCLX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.23 Expected Swing
$1.62 (-12.5%)Spot $1.85$2.08 (+12.5%)
MODEL EARNINGS SETUP GAUGE

SCLX Quantitative Pre-Earnings Setup: 40/100

Trailing EPS: $4.25 • YoY Revenue Growth: -46.5%

Model Bullish Setup (40/100)Model Risk Weight (60/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$30.3M-$374.1M$3.7M98%
FY 20242024-12-31$56.6M-$72.8M$19.3M98%
FY 20232023-12-31$46.7M-$114.3M-$20.7M92%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCLX)

  • ✓Walkthrough of SCLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SCLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.34%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.06H $2.06L $1.85C $1.85VOL 49.9K
RES: $8.73SUP: $1.69SMA50: $4.02SMA200: $5.26
$11.03$8.54$6.04$3.55$1.06RES $8.73SUP $1.69$1.852026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SCLX Butterfly Map → + Track SCLX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -46.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SCLX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SCLX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SCLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCLX)

Health Care Rank #471 of 1016 ⚔️ DYAI vs SCLX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SCLX vs. DYAI, ABOS, PLUR, JSPR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Scilex Holding Company (SCLX) ranks #471 by composite RQD confidence (40/100, grade D-) and #850 by equity capitalization ($15.7M). Within this direct 5-issuer industry benchmark cohort, SCLX leads on earnings valuation at N/A trailing P/E, while SCLX leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. SCLX currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SCLX ACTIVE
Scilex Holding Company
D- 40/100 — 96.0% -35.0% -10.19% $15.7M Benchmark Subject
DYAI
Dyadic International Inc.
E 31/100 — 24.9% -35.0% +5.32% $15.2M /dyai-vs-sclx →
ABOS
Acumen Pharmaceuticals Inc.
E 33/100 — — -35.0% -90.82% $15.2M /abos-vs-sclx →
PLUR
Pluri Inc.
E 34/100 — 49.0% -35.0% +3.33% $16.7M /plur-vs-sclx →
JSPR
Jasper Therapeutics Inc.
D- 36/100 — — -35.0% -2.22% $17.3M /jspr-vs-sclx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001820190

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scilex Holding Company (SCLX) reported GAAP revenue of $30.3M (-46.5% vs. FY2024 revenue of $56.6M , and -35.3% cumulative change since FY2023) , GAAP net income of -$374.1M, operating cash flow of $3.8M, and free cash flow of $3.7M (-81.0% YoY). On the balance sheet, SCLX closed FY2025 with $365.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $30.3M -$374.1M $3.8M $3.7M $365.0M —
FY2024 (FY) 2024-12-31 $56.6M -$72.8M $19.3M $19.3M $93.0M —
FY2023 (FY) 2023-12-31 $46.7M -$114.3M -$20.7M -$20.7M — —

3. SCLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Scilex Holding Company (NASDAQ: SCLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.85 (-10.19% 1D, market cap $15.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCLX ranks #471 in composite RQD confidence.

How does SCLX compare to DYAI and ABOS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and ABOS (Acumen Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCLX?

Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCLX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCLX last traded at $1.85 (-10.19% on volume of 49,895 shares), positioning the stock -53.98% below its 50-day simple moving average ($4.02) and -64.83% below its 200-day simple moving average ($5.26). Across its 52-week range of $1.83 to $16.81, SCLX sits at the 0.1% percentile with a 14-day RSI of 20.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.62 to $2.08).

SCLX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is SCLX's next earnings date?

Based on SEC filing cadence, Scilex Holding Company (SCLX)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is SCLX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for SCLX, spanning a range between $1.62 and $2.08.

Direct Sub-Reports: SCLX RQD Cockpit SCLX 12M Forecast SCLX Earnings & Move SCLX Dividends & DRIP SCLX Insiders & 13F SCLX Whale Options SCLX Profit Sankey SCLX News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SCLX — Scilex Holding Company: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:50:14Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SCLX carries an RQD Score of 40, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are scored as follows:

  • Fundamental Cash Engine: 12 / 20. The pillar notes ROIC of -35% alongside an FCF yield of 21.05%. For a prospective investor, the strong FCF yield sits against a deeply negative return on invested capital, so the cash signal and the profitability signal point in different directions and require closer scrutiny before any conclusion is drawn.
  • Whale 13F Flow: 3 / 20. This is the weakest pillar and is described as covering institutional accumulation and options positioning. A low score here indicates that the institutional-flow signal provides little support for the stock.
  • Insider Conviction: 9 / 20. This pillar covers SEC Form 4 and Congressional PTR cluster flow. A below-midpoint score suggests insider and disclosed-trade activity offers limited conviction support.
  • Macro Regime Fit: 8 / 20. The pillar references a beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity, while the score indicates the macro-regime backdrop is not favorable to the name.
  • Forensic Balance Sheet: 8 / 20. The pillar cites an Altman Z of 2.5, a Piotroski F of 4/9, and a Debt/Equity ratio of 0.5. These readings fall in a middle-to-weak range, and the balance-sheet score signals vulnerability rather than strength.

Taken together, the pillars indicate that the valuation discount (price of $2.06 against a 52-week range of $1.83–$16.81) reflects a deteriorated fundamental and flow picture rather than a clear mispricing. Upside drivers would need to come from a reversal in operating losses or a shift in institutional and insider positioning, neither of which is evidenced in the source data. The rating framework therefore frames SCLX as a high-risk profile where the downside factors currently outweigh the supportive ones.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025 (filed 2025-12-31)$30.3M$-346.0M$-374.1MN/A$3.7M$5.0MN/A
FY 2024 (filed 2024-12-31)$56.6M$-83.4M$-72.8MN/A$19.3M$3.3MN/A
FY 2023 (filed 2023-12-31)$46.7M$-105.4M$-114.3MN/A$-20.7MN/AN/A

Per the SEC financials, revenue declined from $56.6M in FY 2024 to $30.3M in FY 2025, while net loss widened to $-374.1M. Per the market data, net margin is -60% and ROIC is -35%. Per the Roarable RQD rating, the forensic pillar cites an Altman Z of 2.5, a Piotroski F of 4/9, and a Debt/Equity ratio of 0.5, which together describe a balance sheet with limited financial strength. Reported cash of $5.0M against a net loss of $-374.1M highlights liquidity sensitivity in the source data.

Open Questions

  • What drove the revenue decline from $56.6M in FY 2024 to $30.3M in FY 2025, and what products or segments were affected?
  • What explains the $-374.1M net loss in FY 2025 relative to the $-72.8M loss in FY 2024?
  • What is the company's total debt, since the debt field is reported as N/A across all periods?
  • What is the source of the discrepancy between the rounded $0.0B market-cap label in the profile and the $17.5M market-cap figure in the market data?
  • What is the company's EPS and debt position given that EPS is reported as N/A across all periods?

SCLX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Scilex Holding Company (SCLX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SCLX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SCLX Bull vs. Bear Conversation Board — What's Your Call at $1.85?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SCLX 🐻 67% BEARISH CONVICTION
1. Pick Your Side on SCLX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.81 (-12.1%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SCLX (D- • RQD 40/100) a Buy at $2.06?

Welcome to the SCLX (Scilex Holding Company) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.59 (-22.8%)
Spot @ $2.06

Pump the brakes on SCLX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SCLX, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Scilex Holding Company expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.49 (+20.9%)
Spot @ $2.06

SCLX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SCLX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $2.06 (52-wk range $1.83 - $16.81), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%